Stock Track | LeMaitre Vascular Plunges 9% in Pre-Market on Q4 Revenue Miss and Weak Q1 Outlook

Stock Track
02-28

LeMaitre Vascular (LMAT) stock is experiencing a sharp pre-market plunge of 9% on Friday, following the company's fourth-quarter 2024 earnings report and disappointing first-quarter 2025 guidance released after the market close on Thursday.

The medical device maker reported Q4 2024 earnings per share (EPS) of $0.49, in line with analysts' estimates. However, the company's Q4 revenue of $55.7 million missed Wall Street's consensus estimate of $56 million. This revenue miss appears to be the primary driver behind the stock's steep decline in pre-market trading.

Adding to investor concerns, LeMaitre's Q1 2025 revenue guidance of $56.7-$58.7 million also fell short of analysts' expectations, further exacerbating the sell-off. While the company's Q1 EPS guidance range of $0.48-$0.53 was in line with estimates, the weak revenue outlook overshadowed this positive aspect, weighing heavily on the stock's performance.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10